Fat-Derived Stem Cells for Diabetic Kidney Disease: Phase 1 Trial Ends Early With Two Patients
A Mayo Clinic phase 1 trial of arterially delivered autologous fat-derived stem cells for diabetic kidney disease was terminated after enrolling only 2 patients.
Summary
Diabetic kidney disease is a leading cause of kidney failure, and there is strong interest in regenerative therapies that could slow its progression. This Mayo Clinic phase 1 trial planned to test stem cells taken from a patient's own fat tissue (adipose-derived mesenchymal stem/stromal cells) and delivered into the kidney's arteries in adults with progressive diabetic kidney disease. The goals were safety, tolerability, dose effects (a lower and a higher dose) and early signs of efficacy. The trial ran from October 2019 to August 2020 and was terminated with just 2 participants enrolled. The registry entry reports no results, so nothing can be said about safety or benefit. The idea is mechanistically plausible, since these cells are thought to release anti-inflammatory and repair signals, but this record shows only a design and an early stop. It is not evidence that the therapy works or that it is safe.
Detailed Summary
Diabetic kidney disease (DKD) is one of the most common complications of type 2 diabetes and a major driver of kidney failure, cardiovascular risk and shortened healthspan. Existing drugs slow decline but do not reverse damage, which keeps interest high in regenerative approaches.
This registered trial, sponsored by Mayo Clinic, set out to test one such approach. Researchers planned to harvest fat tissue from each participant, expand mesenchymal stem/stromal cells (MSC) from it, and deliver them intra-arterially, meaning through the blood vessels that supply the kidney. The phase 1 design compared a lower and a higher dose. Primary aims were safety, tolerability, dose effect and early signals of efficacy in adults with progressive DKD.
The mechanistic rationale is that MSCs are thought to act mainly through paracrine signaling, releasing factors that dampen inflammation, limit fibrosis and support the microvasculature. Those are processes that matter in the aging kidney as well as the diabetic one. Autologous cells also avoid immune rejection.
The key result is a null of information rather than a finding. The trial started in October 2019, was terminated in August 2020, and enrolled only 2 participants. The registry record supplied here lists no outcome data, no adverse event data and no stated reason for termination. We therefore cannot say whether the cells were safe, whether either dose changed kidney function, or whether any mechanism was engaged.
The implication is modest. The record documents that this specific protocol was attempted and stopped early, a reminder that translating cell therapy into practice is difficult and often slow. Readers should not interpret it as support for or against the approach.
Caveats are substantial. With 2 patients, no controls reported, and no results, no efficacy or safety conclusion is possible. This summary rests only on the registry abstract. Anyone considering stem cell treatments for kidney disease should be wary of commercial clinics offering unproven versions and should discuss options with a nephrologist.
Key Findings
- Phase 1 Mayo Clinic trial tested autologous fat-derived MSCs delivered intra-arterially in progressive diabetic kidney disease.
- Design compared a lower and a higher cell dose for safety, tolerability and early efficacy signals.
- Trial was terminated with only 2 participants enrolled, running October 2019 to August 2020.
- No results, adverse events or reason for termination are reported in the available record, so safety and efficacy are unknown.
Methodology
This is a registered single-sponsor phase 1 dose-comparison trial using autologous adipose-derived MSCs given intra-arterially. Primary aims were safety, tolerability, dose effect and early efficacy signals. Enrollment was 2 and the status is terminated.
Study Limitations
This summary is based on the registry abstract only, with no results posted. With 2 participants, termination and no stated reason, no conclusion on safety, dosing or efficacy is possible. No control group or outcome measures were detailed.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe:
